Cancer: The Major Medical Challenge in Europe Today (Cancer Cures Made in Austria)

Jun 27, 2013

Austria is at the forefront in the fight against cancer in Europe, and plays a leading part in the worldwide campaign, with several pioneering initiatives. Be it innovative immunotherapy, novel molecular targets or radiation therapy, researchers and oncologists throughout Austria are working to develop and commercialise diagnostics and treatments. Sonja Polan at Life Science Austria explains how at the core of Austrian cancer research, multidisciplinary research networks are bringing industry, healthcare and primary research together. [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/06/3-Cancer-The-major-medical-challenge-in-europe-today.pdf” type=”pdf”]Cancer The major medical challenge in europe today[/prettyfilelink] ...

Read More

Some Practical Implications of the UP and the UPC for the Pharmaceutical Sector

Jun 27, 2013

On 19 February 2013, 24 EU member states signed a supra-national agreement which is intended to bring into being a new court called the Uniform Patent Court. This agreement, together with two EU Regulations, the Unitary Patent Regulation (1257/2012) and the Translations Regulation (1260/2012), will finally bring into being something akin to a Community Patent and a Community Patent Court. Neil Jenkins at Bird & Bird LLP explains that to appreciate the implications of this to industry, and in particular the pharmaceutical industry, it is absolutely critical to understand the nature of both the new patent right and the new ...

Read More

Grabbing Hold of the Bar of Success in Drug Development

Jun 27, 2013

Globalisation and other recent developments such as stricter quality control criteria, evolving technologies, and the increasing stringency of regulatory standards, have imposed enormous pressures on biotechnology drug manufacturers. With such difficult basic conditions, only a limited few compounds will ever make it to Phase III, and even fewer will make it through to approval and to commercial manufacturing. Paul Nelles, at Vetter Pharma-Fertigung GmbH & Co. KG, explores whether a contract development and manufacturing organisation (CDMO) can help lower this bar? Or perhaps help to lift you higher, thus helping to improve a company‚Äôs odds of achieving success? [prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2013/06/1-Grabbing-Hold-of-the-Bar-of-Success-in-Drug-Development.pdf” ...

Read More